All In Biotech

Drug Trial Radar · NCT07227779

BPaLMZ for TB Meningitis

A PHASE 2 NOVEL ANTIMICROBIAL COMBINATION THERAPY TO TREAT TUBERCULOUS MENINGITIS

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 312 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

312

Planned (sponsor's estimate)

Start

Jul 28, 2026

Primary completion

Mar 31, 2028

Study completion Sep 30, 2030

Sponsor

Lead sponsor
David BoulwareAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Infectious Diseases Institute, Uganda; University of Minnesota; Brighton & Sussex Medical School; Mbarara University of Science and Technology; Radboud University Medical Center; Meningitis Foundation
First posted
Nov 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This two-stage study will compare consented research participants with tuberculous meningitis receiving experimental Bedaquiline (B), Pretomanid (Pa), Linezolid (L); Moxifloxacin (M), Pyrazinamide (Z) known as (BPaLMZ) to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE. The experimental regimen is known as 1BPaLMZ/5PaM.

Conditions

  • Tuberculous Meningitis
  • HIV
  • Meningitis
  • TB - Tuberculosis

Interventions

  • BPaLMZ RegimenDrug

    bedaquiline, pretomanid, linezolid, moxifloxacin, and pyrazinamide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 24-week SurvivalTime frame: 24 Weeks
  2. Hierarchical composite endpoint (survival time + functional status)Time frame: 24 Weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Infectious Diseases Institute

    Kampala, Uganda · Recruiting

  • Mbarara University of Science and Technology

    Mbarara, Uganda · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.